<4-Pyrrolidino-phenyl>-isopropyl-keton | 92499-98-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: <4-Pyrrolidino-phenyl>-isopropyl-keton
• 英文别名: N-<4-Isobutyryl-phenyl>-pyrrolidin；2-Methyl-1-(4-pyrrolidin-1-ylphenyl)propan-1-one
• CAS: 92499-98-4
• 化学式: C₁₄H₁₉NO
• 分子量: 217.311
• InChiKey: UFSBNZUSZSUVLQ-UHFFFAOYSA-N

物化性质

• 熔点：
  77-80 °C(Solvent: Ligroine)
• 沸点：
  362.2±25.0 °C(predicted)
• 密度：
  1.040±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• PHTHALAZINONES AND ISOQUINOLINONES AS ROCK INHIBITORS
  申请人：Bristol-Myers Squibb Company

  公开号：US20140206686A1

  公开（公告）日：2014-07-24

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了Formula (I)的化合物：或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性的ROCK抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗心血管、平滑肌、肿瘤学、神经病理学、自身免疫、纤维化和/或炎症性疾病的方法。
• SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES
  申请人：Incyte Corporation

  公开号：US20150025056A1

  公开（公告）日：2015-01-22

  The present invention provides compounds of the formula I: its enantiomers, diastereomers, racemic mixtures thereof, prodrugs, crystalline forms, non-crystalline forms, amorphous forms thereof, solvates thereof, metabolites thereof, and pharmaceutically acceptable salts, wherein the ring A substituent groups are fully defined in the following disclosure. The compounds of formula I are inhibitors of metalloproteases such as matrix metalloproteases and sheddases, and are useful in treating diseases such as rheumatoid arthritis, psoriasis, neoplastic diseases, allergies and all those diseases wherein inhibition of MMPs is desirable.

  本发明提供了I式化合物：其对映异构体，对映体混合物，前药，结晶形式，非晶形式，无定形形式，其溶剂化物，其代谢物和药学上可接受的盐，其中环A取代基团在以下披露中得到充分定义。I式化合物是金属蛋白酶抑制剂，如基质金属蛋白酶和剪切酶的抑制剂，并且在治疗风湿性关节炎，牛皮癣，肿瘤性疾病，过敏和所有需要抑制MMP的疾病中有用。
• Phthalazinones and isoquinolinones as rock inhibitors
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10385026B2

  公开（公告）日：2019-08-20

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式 (I) 的化合物： 或其立体异构体、同系物或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性 ROCK 抑制剂。本发明还涉及包含这些化合物的药物组合物，以及使用这些化合物治疗心血管、平滑肌、肿瘤、神经病理、自身免疫、纤维化和/或炎症性疾病的方法。
• US9221767B2
  申请人：——

  公开号：US9221767B2

  公开（公告）日：2015-12-29
• US9440958B2
  申请人：——

  公开号：US9440958B2

  公开（公告）日：2016-09-13